临床中断化合物的综合分析,使用体外二次药理学小组预测药物开发期间潜在的安全风险
Verena Albert1, Danielle E Skinner1, Saloni Karnwal1
1Eurofins DiscoverX, LLC, 11180 Roselle Street, Suite D, San Diego, California 92121, United States of America.
ACS pharmacology & translational science
|September 19, 2025
概括
在体外二次药理学早期选潜在的药物负债. 使用像SAFETYscan47这样的平台的安全药理方法有助于减少临床试验失败并提高患者安全.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药物发现 药物发现 药物发现
- 毒理学 毒理学 毒理学
背景情况:
- 在体外二次药理学对于在药物发现中识别非目标相互作用至关重要.
- 早期评估潜在的负债减少了临床消耗,提高了患者的安全.
- 安全药理分析是领先候选人的标准方法.
研究的目的:
- 突出在临床前药物发现中体外药理学分析的有用性.
- 展示如何评估来自SAFETYscan47等平台的数据可以减轻风险.
- 通过改善早期化合物评估,支持患者安全并减少临床磨损.
主要方法:
- 使用高通量选平台 (SAFETYscan47) 进行广泛的目标分析.
- 分析发现化合物的体外二次药理学数据.
- 将临床失败的候选药物与更广泛的化合物数据集进行比较.
主要成果:
- 高通量选可快速识别化合物中的潜在负债.
- 试验室分析 (in vitro profiling) 在临床前阶段为化合物安全提供了宝贵的见解.
- 对失败候选药物的分析有助于减轻新药发现中的风险.
结论:
- 试管二次药理对于减少临床磨损至关重要.
- 像SAFETYscan47这样的平台有助于早期发现和减轻毒品负债.
- 强大的临床前安全概况最终支持患者安全和成功的药物开发.
相关概念视频
Preclinical Development: Overview
5.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.8K
Drug Discovery: Overview
11.1K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
11.1K
Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
Drug Product Performance: In Vitro–In Vivo Correlation
231
In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while...
231
In Vitro Drug Release Testing: Overview, Development and Validation
311
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
311
Clinical Trials: Overview
4.6K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.6K


